Neoleukin Therapeutics IncChange company Symbol lookupSelect an option...NLTX Neoleukin Therapeutics IncHARP Harpoon Therapeutics IncVIRC Virco Mfg CorpRVLP RVL Pharmaceuticals PLCTRGP Targa Resources CorpRCRT Recruiter.Com Group IncVGAS Verde Clean Fuels IncDHHC DiamondHead Holdings CorpEJH E-Home Household Service Holdings LtdFLGC Flora Growth CorpGo
Change company Symbol lookup
Select an option...
NLTX Neoleukin Therapeutics Inc
HARP Harpoon Therapeutics Inc
VIRC Virco Mfg Corp
RVLP RVL Pharmaceuticals PLC
TRGP Targa Resources Corp
RCRT Recruiter.Com Group Inc
VGAS Verde Clean Fuels Inc
DHHC DiamondHead Holdings Corp
EJH E-Home Household Service Holdings Ltd
FLGC Flora Growth Corp
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Health Care : Biotechnology | Small Cap Value
Company profileNeoleukin Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. The Company's lead product candidate, NL-201, is an interleukin-2 (IL-2)/ interleukin-15 (IL-15) immunotherapy designed to eliminate binding to the alpha subunit of the IL-2 receptor (also known as CD25) while enhancing binding to the beta and gamma subunits. NL-201 is designed to mimic the therapeutic activity of the cytokines IL-2 and IL-15 for the treatment of various types of cancer, including renal cell carcinoma (RCC), melanoma and hematological malignancies. Its Neoleukin platform uses a set of advanced computational algorithms and methods to design functional de novo proteins. NL-201 holds promise in combination with cell therapy to expand and maintain populations of transplanted CAR-T and natural killer (NK) cells.
|
|
|
|
| |
| Latest Earnings Missed Consensus (Q4 ending 12/2022) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q4 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced March 20, 2023 | -$0.24 | Q4 Consensus of 2 analysts | -$0.19 | Difference from consensus | -26.32% | Q1 Earnings will announce | (Unconfirmed) May 8, 2023 |
Quarterly Earnings History and Estimates
Show high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
NLTX's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.